Broad Spectrum Distillate
CBD Isolate
CBG Isolate
Water Soluble CBD
Back to news
23. December 2021
Corporate News Global Market Watch Medical News Pharmaceutical

Pfizer’s Acquisition of Arena Signals Mainstream Appeal for Cannabinoid Medicines

Pfizer announced on Monday a definitive agreement to acquire all the outstanding shares of cannabinoid medicines specialist Arena for US$100 per share in an all-cash deal, valuing Arena for about US$6.7bn. 

Through this acquisition Pfizer plans to gain access to Arena’s auto-immune therapy Etrasimod. Based in Park City, Utah, Arena Pharmaceuticals is a biopharmaceutical company that develops a diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology, and cardiology. According to the press release, Arena has built a robust development program for etrasimod, including two Phase 3 studies in ulcerative colitis (UC), a Phase 2/3 program in Crohn’s Disease, a planned Phase 3 program in atopic dermatitis, and ongoing Phase 2 studies in eosinophilic esophagitis and alopecia areata.

Pfizer is using its newfound vaccine related cash to acquiring several companies and the announcement to acquire Arena comes less than a month after Pfizer closed its $2.2 billion deal to acquire Trillium Therapeutics.

Continue reading on